Table 3.
Determinants of time to achieve PtGA ≤ 20 mm and achievement at week 100 among guselkumab-randomized patients (N = 493)
| Independent baseline variables | Time to PtGA ≤ 20 mm achievement | Achievement of PtGA ≤ 20 mm at W100 | ||
|---|---|---|---|---|
| HR (95% CI) | OR (95% CI) | |||
| All covariates | Backward selection | All covariates | Backward selection | |
| Age, years | 1.00 (0.99–1.01) | - | 1.00 (0.98–1.02) | - |
| Sex (male vs. female) | 1.12 (0.89–1.41) | - | 1.35 (0.91–2.00) | - |
| Race (White vs. Asian) | 0.85 (0.36–1.97) | - | 0.99 (0.24–4.03) | - |
| BMI, kg/m2 | 0.99 (0.97–1.01) | - | 0.98 (0.95–1.02) | - |
| Guselkumab treatment (Q4W vs. Q8W) | 0.96 (0.76–1.21) | - | 1.00 (0.68–1.48) | - |
| HAQ-DI score (0–3) | - | - | - | - |
| PtGA VAS (0–10 cm) | 0.88 (0.82–0.95)† | 0.87 (0.81–0.93) ‡ | 0.85 (0.75–0.96)† | 0.82 (0.74–0.92) † |
| Pt Pain VAS (0–10 cm) | - | - | - | - |
| FACIT-Fatigue§ | 1.01 (1.00–1.03) | - | 1.02 (0.99–1.04) | - |
| History of depression (N = 8) | 1.36 (0.56–3.33) | - | 1.31 (0.30–5.84) | - |
| Suicidal ideation or non-suicidal self-injurious behaviour (N = 9) | 1.06 (0.39–2.88) | - | 0.57 (0.14–2.40) | - |
| History of fibromyalgia (N = 3) | 0.71 (0.56–0.91)† | 0.70 (0.55–0.88) † | 0.59 (0.39–0.87)† | 0.56 (0.38–0.83) † |
BMI = body mass index; CI = confidence interval; FACIT = Functional Assessment of Chronic Illness Therapy; HAQ-DI = Health Assessment Questionnaire-Disability Index; HR = hazard ratio; OR = odds ratio; Pt = patient; PtGA = patient global assessment; Q4W = every 4 weeks; Q8W = every 8 weeks; VAS = visual analog scale; W = week
*p < 0.05; †p < 0.01; ‡p ≤ 0.0001
§Higher score indicates less fatigue